Morphine gluconate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Morphine gluconate
• 英文别名: (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
• 化学式: C23H31NO10
• 分子量: 481.5
• InChiKey: VVKNQMNKCCLCFP-TZGOMOPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.29
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  191
• 氢给体数：
  8
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  吗啡硫酸盐甲醇 、 sodium D-gluconate 生成 Morphine gluconate
  参考文献：
  名称：

  Compositions and methods comprising morphine gluconate

  摘要：

  本发明涉及一种药物组合物，其中包括吗啡葡萄糖酸盐或其化学等效物。在一种实施例中，本发明包括一种制备吗啡葡萄糖酸盐或其化学等效物的方法，即通过将吗啡硫酸盐与葡萄糖酸钠混合。本发明还包括一种在哺乳动物中引起镇痛或麻醉反应的方法，其中包括向哺乳动物中给予包括吗啡葡萄糖酸盐或其化学等效物的治疗有效量的药物组合物。

  公开号：

  US06225343B1

文献信息

• MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME
  申请人：Teika Pharmaceutical Co., Ltd.

  公开号：EP2123274A1

  公开（公告）日：2009-11-25

  An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc. This transdermal absorption preparation comprises a medicinal composition for transdermal absorption in which an active ingredient selected from morphine and salts thereof is blended in such an amount as corresponding to the saturation solubility or more in an active ingredient-holding vehicle having fluidity at a temperature around the human skin surface temperature and at least a portion of the active ingredient is held in a crystalline form, characterized in that, in the case where a preparation obtained from the above-described medicinal composition for transdermal absorption is applied to the uninjured skin of the back of a white rabbit having been shaven with electrical clippers for 72 hours, the available amount of the active ingredient per single dose of the preparation is from 10 mg to 400 mg in terms of morphine base, and the plasma concentrations of the active ingredient 24 hours and 48 hours after the application of the preparation under the above-described conditions are each at least 40 ng/mL in terms of morphine base, and so on.

  本发明的目的是提供一种透皮吸收制剂，能够在至少 48 小时内将血液中的吗啡浓度维持在有效水平等。这种透皮吸收制剂包括一种用于透皮吸收的药物组合物，其中的活性成分选自吗啡及其盐类，其用量相当于在人体皮肤表面温度附近具有流动性的活性成分保持载体中的饱和溶解度或更高，并且至少有一部分活性成分以结晶形式保持，其特征在于、将上述药物组合物制得的透皮吸收制剂涂抹在用电剪剃过毛的白兔背部未受伤的皮肤上 72 小时的情况、以吗啡碱计，每次单剂量制剂中有效成分的可用量为 10 毫克至 400 毫克；以吗啡碱计，在上述条件下使用制剂 24 小时和 48 小时后，有效成分的血浆浓度均至少为 40 纳克/毫升，等等。
• Nasal aromatherapy dispenser clip
  申请人：——

  公开号：US20040079814A1

  公开（公告）日：2004-04-29

  An intra nasal dispenser clip for aromatherapy and for dispensing fragrances or aromatically odorous medicine includes a bendable arcuate band extending between distal ends. The ends have a pair of hollow aroma or aromatically odorous medicine dispensing containers, with hollow fragrant aroma dispensing containers affixed thereat. The hollow aroma or aromatically odorous medicine dispensing containers applying the fragrant or medically active aroma directly within the nostrils of the person using the clip. The band contacts the respective right and left sides of a user's nasal septum, with the band wrapped around the distal end of the nasal septum. The arcuate band is gentle on the nasal septum due to the geometry of the arcuate band being a wide circular arc bottom spring member, with inflection points at either distal ends, from which shorter reversed circular arcs emerge with the hollow aroma-dispensing containers at their distal ends.

  一种用于芳香疗法和分配香料或芳香气味药物的鼻内分配器夹子包括一条在远端之间延伸的可弯曲弧形带。两端有一对中空的芳香或芳香气味药物分配容器，其上贴有中空的芳香分配容器。中空的芳香或芳香药物分配容器将芳香或药物活性芳香直接注入使用夹子的人的鼻孔中。带子分别接触使用者鼻中隔的左右两侧，带子缠绕在鼻中隔的远端。弧形带对鼻中隔很温和，这是因为弧形带的几何形状是一个宽的圆弧形底部弹簧部件，两端的远端有拐点，从拐点处出现较短的反向圆弧，其远端有中空的香气分发容器。
• Device and method for delivery of combination nasal medication
  申请人：Lane M. Edward

  公开号：US20060207596A1

  公开（公告）日：2006-09-21

  The present invention relates to dual nasal spray applicator devices and systems for administration of two nasal compositions in one spray or aerosol dose without mixing of the compositions prior to administration and methods of treatment using these devices and systems. The devices allow incompatible drug or other compositions to be stored and administered by a single device in a single dose, remaining separated until just prior to or during administration of the medications.

  本发明涉及双鼻喷雾器装置和系统，用于在一次喷雾或气溶胶剂量中给药两种鼻腔组合物，给药前组合物无需混合，还涉及使用这些装置和系统的治疗方法。这些装置可将不相容的药物或其他组合物储存在一个装置中，并以一个剂量给药，在给药前或给药过程中保持分离。
• COMPOSITIONS AND METHODS COMPRISING MORPHINE GLUCONATE
  申请人：NASTECH PHARMACEUTICAL COMPANY, INC.

  公开号：EP1185171A1

  公开（公告）日：2002-03-13
• EP1185171A4
  申请人：——

  公开号：EP1185171A4

  公开（公告）日：2004-09-29